Packages (Simulation)
Reagent Preparation
Image (I)
-
Results demonstration
Image (II)
-
Typical Standard Curve
Quality Guarantee
Instruction Manual
Certificate
Multiplex Assay Kit for Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay)
phosphatidylcholine-sterol O-acyltransferase; Phospholipid-cholesterol acyltransferase
(Note: Up to 8-plex in one testing reaction)
- Product No.LMJ516Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.01-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.003 ng/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 449
US$ 467
US$ 492
US$ 527
US$ 562
US$ 613
US$ 691
US$ 864
Add to Price Calculator
Result
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 81-92 | 86 |
| EDTA plasma(n=5) | 95-103 | 99 |
| heparin plasma(n=5) | 95-103 | 99 |
| sodium citrate plasma(n=5) | 78-103 | 91 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Lecithin Cholesterol Acyltransferase (LCAT) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 93-105% | 87-102% | 82-89% | 83-97% |
| EDTA plasma(n=5) | 94-103% | 87-97% | 81-101% | 98-105% |
| heparin plasma(n=5) | 88-97% | 88-98% | 91-99% | 80-93% |
| sodium citrate plasma(n=5) | 86-101% | 78-95% | 83-95% | 80-92% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:LCAT) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| Int J Rheum Dis | Plasma phospholipase, γ‐CEHC and antioxidant capacity in fibromyalgia PubMed: 26585319 |
| Inflammation. | Alteration of Lysophosphatidylcholine-Related Metabolic Parameters in the Plasma of Mice withExperimental Sepsis. pubmed:28028754 |
| British journal of cancer | A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. pubmed:28664912 |
| Journal of Agricultural and Food Chemistry | Lipid-lowering effects of medium-chain triglyceride-enriched coconut oil in combination with licorice extracts in experimental hyperlipidemic mice Pubmed: 30244576 |
| Experimental and Therapeutic Medicine | Identification and validation of differentially expressed proteins in serum of CSU patients with different duration of wheals using an iTRAQ labeling, 2D‑LC‑MS/MS Doi: 10.3892/etm.2018.6818 |
| British Journal of Cancer | Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. Pubmed: 31388184 |
| BIOMEDICINE & PHARMACOTHERAPY | The synergistic mechanism of total saponins and flavonoids in Notoginseng− Safflower pair against myocardial ischemia uncovered by an integrated … Pubmed: 32739736 |
| Biomedicine & Pharmacotherapy | Pharmacokinetics/pharmacometabolomics-pharmacodynamics reveals the synergistic mechanism of a multicomponent herbal formula, Baoyuan decoction?¡ |
| Cell Metab | Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression Pubmed:35235775 |